All News
Weak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.
Read Article
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.
Functional Precision Medicine in Rheumatoid Arthritis
Novel research from the Medical University of Vienna demonstrates the plausible utility of functional precision medicine using immunophenotyping of blood cells with rheumatoid arthritis, to help guide treatment selection.
Read Article
Fallen Angels (1.17.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
Read Article
Childhood Maltreatment and the Risk of Rheumatic Diseases
EurekAlert!
A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.
Read Article
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
Worldwide, it is estimated that arthralgia treatments cost USD 4.7 Billion in 2024 and is estimated to reach USD 9.0 Billion by 2035. https://t.co/DYnbhpLAhr https://t.co/sKR8sssKNx
Dr. John Cush RheumNow ( View Tweet)
French cross-sectional study of pts on stable sc MTX x several yrs. Examined MTX polyglutamates (MTX-PGs) & disease activity in 34 RA pts (25 remission). + correlation between RA remission & high MTX-PG3 levels in pts w/ BMI <25. BMI may limit utility of PG3 levels… https://t.co/scFzVy7hhA https://t.co/sUQUHFbhaG
Dr. John Cush RheumNow ( View Tweet)
RA higher risk of Celiac Dz -- Rheumatic Dz administrative data review (2004–2013)compared 70,061 #RA w/ 276,895 controls, median F/U 9 yrs. (IQR 9–9). Celiac Prevalence higher in RA (171/70,061 = 0.24% vs 398/276895 = 0.14%; p < 0.001), more so in females w/ RA… https://t.co/SayZYvkZpV https://t.co/fcuyJ5sFk0
Dr. John Cush RheumNow ( View Tweet)
Head-to-Head Clinical Trials
https://t.co/kLwVKRcnna https://t.co/XDhk9VAIin
Dr. John Cush RheumNow ( View Tweet)
Study of predominantly older males from the Veterans Health Administration (VHA) data, shows the use of b/ts-DMARDs is not associated with a risk for multiple myeloma. From 27,540 RA pts, 30% took b/tsDMARD, 77 incident MM (HR1.32;95% CI 0.78, 2.26) https://t.co/KZLEfq8vRK https://t.co/7qLQISRCoC
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Natural RA
PsO/PsA patient avoiding DMARDs and Biologics, and wants Natural therapies
Features Dr. Jack Cush
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/nYhcPaC0qW https://t.co/wT80JoY4OE
Dr. John Cush RheumNow ( View Tweet)
Childhood Maltreatment and the Risk of Rheumatic Diseases
A UK retrospective matched open cohort study shows that children who suffered from abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life.… https://t.co/f0XMDJbvvg https://t.co/9KvpixsNFL
Dr. John Cush RheumNow ( View Tweet)
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM
Dr. John Cush RheumNow ( View Tweet)
VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi
Dr. John Cush RheumNow ( View Tweet)
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/Va9Z0NWHj9 https://t.co/ciM7QtEF5S
Dr. John Cush RheumNow ( View Tweet)
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/IB7aS6IKgT https://t.co/0zN5N7w65l
Dr. John Cush RheumNow ( View Tweet)
Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4 https://t.co/CBHxzBc9XQ
Dr. John Cush RheumNow ( View Tweet)
Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22 https://t.co/n8ncKG9SFt
Dr. John Cush RheumNow ( View Tweet)
Phase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis (PsA).… https://t.co/yKBV91dR8z https://t.co/nndnpYheNu
Dr. John Cush RheumNow ( View Tweet)
